| 2017-12-13 07:08:29|
IOVA, AZN 07:08 12/13 12/13/17
Iovance Biotherapeutics expands pipeline of TIL therapies into lung cancer
Iovance Biotherapeutics (IOVA) announced that patient enrollment has begun in a study combining TIL and nivolumab in advanced non-small cell lung cancer, or NSCLC, patients in collaboration with researchers at H. Lee Moffitt Cancer Center and Research Institute (Moffitt), Stand Up to Cancer and other partners. The company also announced that a Phase 2 study in PD-1/PDL-1 naive NSCLC patients, sponsored by Iovance, in collaboration with MedImmune, the global biologics research and development arm of AstraZeneca (AZN), will initiate in the first half of 2018. The study with MedImmune will allow for enrollment of NSCLC patients for treatment with LN-145 alone or in combination with durvalumab.